

S 2891

Fighting the Opioid Epidemic with Sunshine Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: May 22, 2018

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (May 22, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/2891>

Sponsor

Name: Sen. Grassley, Chuck [R-IA]

Party: Republican • **State:** IA • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Blumenthal, Richard [D-CT]	D · CT		May 22, 2018
Sen. Brown, Sherrod [D-OH]	D · OH		May 22, 2018
Sen. Manchin, Joe, III [D-WV]	D · WV		Sep 4, 2018

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	May 22, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 S 3120	Related bill	Jun 25, 2018: Placed on Senate Legislative Calendar under General Orders. Calendar No. 484.
115 S 308	Related bill	Feb 6, 2017: Read twice and referred to the Committee on Finance.

Fighting the Opioid Epidemic with Sunshine Act of 2018

This bill expands Medicaid and Medicare reporting requirements related to the transparency of physician ownership or investment interests.

Under current law, a manufacturer of drugs, devices, or medical supplies that are covered under Medicaid or Medicare must regularly report on any payment or transfer of value by the manufacturer to a “covered recipient,” defined as either a physician who is not an employee of the manufacturer or a teaching hospital. The bill expands the definition of “covered recipient” to also include any of the following practitioners who is not an employee of the manufacturer: (1) a physician assistant, (2) a nurse practitioner, (3) a clinical nurse specialist, (4) a certified registered nurse anesthetist, or (5) a certified nurse-midwife.

Actions Timeline

- **May 22, 2018:** Introduced in Senate
- **May 22, 2018:** Read twice and referred to the Committee on Finance.